Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818508 | 0.85 | HTR6 (0.50) | HTR6CYP3A4ALDH1A1MAPK1LMNA | |
| SCHEMBL5609530 | 0.78 | NAPRT (0.53) | NAMPTHTR6ABCC9ABCC8KCNJ11 | |
| SCHEMBL14029083 | 0.76 | HTR6 (0.70) | NAMPTHTR6ALDH1A1LMNATSHR | |
| SCHEMBL164409 | 0.76 | HTR6 (0.70) | HTR6ALDH1A1TSHR | |
| SCHEMBL3781114 | 0.74 | ALDH1A1 (0.42) | HTR6CYP3A4ALDH1A1MAPK1LMNA | |
| SCHEMBL5760553 | 0.74 | NAMPT (0.39) | NAMPTHTR6LMNATSHRTXNRD1 | |
| SCHEMBL10605735 | 0.73 | GAA (0.73) | NAMPTALDH1A1LMNAGAA | |
| SCHEMBL5304096 | 0.73 | PTGS1 (0.51) | NAMPTHTR6CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL9243675 | 0.73 | ALDH1A1 (0.73) | HTR6CYP3A4ALDH1A1MAPK1LMNA | |
| SCHEMBL8866128 | 0.73 | TSHR (0.73) | HTR6CYP3A4ALDH1A1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-117015381-A | Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116096413-A | Anti-human VISTA antibodies and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4136118-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-109415337-B | Piperidine as multiple endocrine adenoma protein inhibitor | 密执安大学评议会 | 2022-01-18 | — | — | CN | disclosed |
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
| WO-2021216913-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3452461-A1 | PIPERIDINES AS MENIN INHIBITORS | The Regents Of The University Of Michigan Office Of Technology Transfer (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2018183857-A1 | PIPERIDINES AS COVALENT MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2017192543-A1 | PIPERIDINES AS MENIN INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2008053199-A1 | COMBINATION THERAPY FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
| EP-1562902-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | MEN1, BRCA1, KRAS | NAMPT 2284/4885HTR6 630/4885ABCC9 3538/4885 |
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | NAMPT 4467/4885HTR6 1087/4885ABCC9 4315/4885 |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | NAMPT 690/4885HTR6 3382/4885ABCC9 3520/4885 |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | NAMPT 89/4885HTR6 2643/4885ABCC9 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.